Is a three‑fold increase in urinary estrone‑3‑glucuronide (E1G) between days 7–8 and again between days 9–10 after the luteinizing hormone (LH) surge consistent with early pregnancy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 22, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

E1G Patterns and Early Pregnancy Detection

A three-fold increase in urinary estrone-3-glucuronide (E1G) occurring between days 7–8 and again between days 9–10 after the LH surge is NOT consistent with typical early pregnancy patterns and suggests either measurement error, assay variability, or a non-viable pregnancy.

Normal E1G Patterns in Early Pregnancy

In viable pregnancies, E1G follows a predictable trajectory after implantation:

  • E1G typically rises gradually in early pregnancy, not in repeated three-fold jumps over consecutive 24-hour periods 1
  • The normal pattern shows E1G elevation beginning in the early luteal phase (approximately 3–6 days post-LH surge), with levels increasing as the corpus luteum produces estrogen 2
  • In conception cycles, E1G concentrations show a sustained rise rather than dramatic fold-increases over single days 3, 4

Why Your Pattern Is Atypical

The Reported E1G Values Are Problematic

Your described pattern shows:

  • Day 7 post-LH: E1G = 43 (baseline)
  • Day 8 post-LH: E1G = 129 (three-fold increase from day 7)
  • Day 9 post-LH: E1G = 40 (return to baseline)
  • Day 10 post-LH: E1G = 120 (three-fold increase from day 9)

This oscillating pattern with repeated three-fold increases followed by drops to baseline is inconsistent with any known physiologic process in early pregnancy 5, 3

Normal Early Pregnancy E1G Kinetics

  • In viable pregnancies, urinary hCG (which drives corpus luteum function and thus E1G production) increases 3-fold between the day of detection and the next day, but this rate of rise decreases thereafter to approximately 1.6-fold by days 6–7 post-implantation 1
  • E1G follows corpus luteum function and does not show the same rapid doubling pattern as hCG 2, 3
  • The seven-fold increase in E1G from early follicular to luteal phase values occurs gradually over the entire luteal phase, not in 24-hour intervals 3

Diagnostic Interpretation

Most Likely Explanations

  1. Assay variability or measurement error: The oscillating pattern suggests technical issues with sample collection, storage, or analysis 3
  2. Incorrect timing relative to LH surge: If the LH surge was misidentified, the day-counting would be inaccurate 5, 4
  3. Non-viable pregnancy: Abnormal hormone patterns can occur with ectopic pregnancy or early pregnancy loss 2

What Would Be Expected in Early Pregnancy

  • Sustained progressive rise in E1G beginning around day 3–6 post-LH surge 2, 3
  • E1G levels in the luteal phase should be approximately seven-fold higher than early follicular phase baseline, but this increase occurs gradually 3
  • The ratio of E1G to pregnanediol-3-glucuronide (PDG) shows a sustained decrease over at least 9 consecutive days in viable pregnancies, not oscillating increases 5

Critical Pitfalls to Avoid

  • Do not rely on single E1G measurements to confirm pregnancy; serial measurements showing a sustained rise are required 3, 4
  • Day-to-day coefficient of variation for E1G can be as high as 25–40% even when corrected for creatinine, making single-day comparisons unreliable 3
  • E1G peaks are delayed by approximately 1 day compared to plasma estradiol peaks, so timing relative to ovulation must account for this lag 3, 4
  • Three-fold increases over 24 hours are not physiologic for E1G in any phase of the cycle or early pregnancy 5, 1, 3

Recommended Next Steps

Obtain serum quantitative β-hCG testing immediately to establish whether pregnancy is present and viable, as E1G patterns alone cannot confirm pregnancy status 6, 7

  • If β-hCG is positive, repeat in exactly 48 hours to assess for appropriate doubling (53–66% increase expected in viable intrauterine pregnancy) 6, 7
  • Perform transvaginal ultrasound when β-hCG reaches 1,000–3,000 mIU/mL to confirm intrauterine location 6
  • Discontinue reliance on E1G measurements for pregnancy confirmation, as the pattern you describe is not interpretable within known physiologic parameters 5, 3

Related Questions

Does estrone (e1g) level increase 7-10 days post peak in the luteal phase in a female patient of reproductive age, and if so, how much does it rise above baseline levels?
What is the typical time lag, in hours, between changes in circulating estrogen (estradiol) and urinary estrone‑3‑glucuronide (E1G) concentrations?
In a reproductive‑age woman tracking urinary estrone‑3‑glucuronide (E1G), does the level drop after embryo implantation or remain elevated/increase?
Does estrone‑3‑glucuronide (E1G) dip during embryo implantation in a reproductive‑age woman?
On cycle day 9 with an estrone‑3‑glucuronide (E1G) level of 8.5 after a 4.5‑hour sample hold and only 2 hours of sleep, am I currently in the fertile window?
How should I interpret and manage an arterial blood gas with pH 7.23, pCO₂ 95 mm Hg, bicarbonate 39.8 mmol/L, and base excess +8.4?
Can diuretics cause azotemia?
I am an asymptomatic adult with no known liver disease or hepatotoxic medication use; my alanine aminotransferase is 5 U/L and total bilirubin is <0.3 mg/dL—what does this indicate and is any treatment required?
What beta‑blocker is preferred after an acute myocardial infarction in an adult patient without contraindications such as severe bradycardia, high‑grade atrioventricular block, uncontrolled asthma, or acute decompensated heart failure?
What are the latest advances in the management of chronic kidney disease that do not involve transplantation?
What laboratory and imaging studies are recommended to evaluate a patient with suspected acute glomerulonephritis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.